Skip to main content

Cisbio, Blue Sky Collaborate on Kinase Assay Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cisbio Bioassays and Blue Sky BioProducts today announced a partnership combining their technologies for the development of assays for target kinases.

The partnership will combine Cisbio's homogenous time resolved fluorescence technology, or HTRF, with Blue Sky's TDA 2.0 technology. TDA 2.0 is a stable solution of lipid-based nanoparticles with nickel-chelating moieties and serves as a template for the assembly of purified His-tagged proteins normally associated with membranes, Cisbio said in a statement.

The deal is expected to result in assays with "unparalleled sensitivity for obtaining better biologically enhanced results on target kinases," Cisbio said.

"Through HTRF, Cisbio Bioassays has developed extensive expertise in the field of kinase enzyme screening tools," said François Degorce, director of marketing and communications for Cisbio. "The combination of these two proven technologies in this area allows us to provide an even more robust and efficient solution for studying these key therapeutic targets, particularly in oncology research."

Based in Worcester, Mass., Blue Sky provides contract research organization services to pharmaceutical firms.

Terms of the deal were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.